Companies › Kiniksa Pharmaceuticals International
1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KPL-387 | – | Phase 2 | Pericarditis; Recurrent Pericarditis | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07010159 | KPL-387 | Phase 2 | Pericarditis | Cardiovascular | Dec 2027 |
| NCT07288216 | KPL-387 | Phase 2 | Recurrent Pericarditis | Cardiovascular | Dec 2027 |
Cash and short-term investments of $569m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Thryv Therapeutics Theravance Biopharma Boston Scientific Tectonic Therapeutic Tectonic Operating Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.